Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Stopped early · Phase 2

Conditions studied: Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer

In brief

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Key facts

Study ID

NCT03397394

Run by

pharmaand GmbH

People needed

97

Starts

2018-06-01

Expected to finish

2020-01-15

Last updated by the study team

2023-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
• Received 1 or 2 prior treatment regimens for advanced or metastatic disease
• Confirmed radiologic disease progression during or following recent treatment
• Mandatory biopsy is required during screening
• Measurable disease per RECIST v1.1
• Adequate organ function
• ECOG 0 or 1

You may not qualify if…

• Prior treatment with a PARP inhibitor
• Symptomatic and/or untreated CNS metastases
• Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

Where it is running

• University of California San Diego (UCSD), Moores Cancer Center — La Jolla, California, United States
• University of California, Los Angeles (UCLA) — Los Angeles, California, United States
• Universityof California, Irvine — Orange, California, United States
• Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California, United States
• Stanford University School of Medicine — Stanford, California, United States
• Hartford Health Care Cancer Institute — Hartford, Connecticut, United States
• Eastern Connecticut Hematology & Oncology Associates (ECHO) — Norwich, Connecticut, United States
• Medstar Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Miami Cancer Institute, Baptist Health South Florida — Miami, Florida, United States
• Northwestern University, Chicago — Chicago, Illinois, United States
• Indiana University - Melvin and Bren Simon Cancer Center (IUSCC) — Indianapolis, Indiana, United States
• The University of Iowa and Holden Comprehensive Cancer Center — Iowa City, Iowa, United States
• Norton Cancer Center — Louisville, Kentucky, United States
• Ochsner Cancer Institute — New Orleans, Louisiana, United States
• University of Maryland, Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Minnesota Oncology Hematology P.A. (USO - US Oncology) — Minneapolis, Minnesota, United States
• Comprehensive Cancer Centers of Nevada (CCCN) — Las Vegas, Nevada, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• University of New Mexico UNM Cancer Research and Treatment Center — Albuquerque, New Mexico, United States
• New York Oncology Hematology, P.C. (USO - US Oncology) — Albany, New York, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• New York - Presbyterian Hospital-Weill Cornell Medical Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Pinnacle Oncology, Honor Health — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.